MIRA Pharmaceuticals Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for MIRA Pharmaceuticals stock have an average target of 14, with a low estimate of 11 and a high estimate of 17. The average target predicts an increase of 1,047.54% from the current stock price of 1.22.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$11	$14	$17	$17
Change	+801.64%	+1047.5%	+1293.4%	+1293.4%

* Price targets were last updated on Sep 30, 2024.

Analyst Ratings

The average analyst rating for MIRA Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25
Strong Buy	2	2
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Elemer Piros Rodman & Renshaw	Rodman & Renshaw	Strong Buy Initiates $17	Strong Buy	Initiates	$17	+1,293.44%	Sep 30, 2024
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Initiates $11	Strong Buy	Initiates	$11	+801.64%	Aug 5, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.55

from -0.51

EPS Next Year

-0.39

from -0.55

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-	-0.17	-0.40	-0.86	-0.51	-0.55	-0.39
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025	2026
High	-0.57	-0.25
Avg	-0.55	-0.39
Low	-0.53	-0.52

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.